NRX Pharmaceuticals Inc. (NRXP) is an American biopharmaceutical company dedicated to the development of innovative medicines to treat underserved neurological disorders and life-threatening conditions. The company is committed to delivering effective treatment options that can improve the quality of life for patients and provide new hopes for complex cases.
NRX Pharmaceuticals was founded on the understanding that new, innovative treatments are needed for diseases that currently have inadequate therapies. Operating on the cutting-edge of drug discovery and development, the company's primary area of focus is on neurological disorders, including those that are life-threatening.
One of the leading candidates in its pipeline of treatment options is ZYESAMI™ (Aviptadil), a synthetic form of the human Vasoactive Intestinal Polypeptide (VIP) which has shown potential in treating critical Covid-19 in patients with respiratory failure. VIP is naturally produced in the lungs and has been shown in numerous studies to have potent anti-inflammatory/anti-cytokine activity in animal models of respiratory distress, acute lung injury, and inflammation.
The company is also working on a non-opioid treatment for suicidal ideation and behavior, NRX-101. It received a Breakthrough Therapy Designation by the FDA for the treatment of severe bipolar depression in patients with Acute Suicidal Ideation and Behavior (ASIB) following an initial approval for a phase 2b/3 study.
NRXP operates under the leadership of a team of executives and scientists with a wealth of experience in the pharmaceutical and biotech industries. This includes Jonathan Javitt, MD, MPH, the company's CEO and Founder, who is a trained neurologist and ophthalmologist.
The company also stands committed to its corporate social responsibility, with a framework that ensures that its business practices support health, sustainability, and corporate citizenship. NRX Pharmaceuticals prioritizes a culture of accountability, ensuring they work responsibly and ethically in the interest of patients, employees, and the global community.
From its inception, NRX Pharmaceuticals Inc. has strived to make a significant difference in patients' lives. Whether it's through groundbreaking treatments for Covid-19 or novel therapies for mental health conditions, the company continues to be driven by the desire to address unmet medical needs, innovate healthcare solutions, and enhance patient outcomes.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
NRX Pharmaceuticals Inc. (NRXP) stock has fallen by 16.92% due to intensified operational and financing risks, with its price dropping from over $3.60 to around $2. The company, an early-stage CNS biotech, faces significant unprofitability, negative equity, and high dependence on external financing, making it a high-risk, speculative investment. Analysts maintain a negative sentiment, citing weak demand, stretched valuations, and an unfavorable risk/reward profile without clear clinical catalysts.
NRx Pharmaceuticals, a biotech firm founded a decade ago, has secured its first FDA approval for a product. Despite this significant achievement, the company's shares experienced a tumble. The article highlights this contrasting outcome, where a major regulatory success did not translate into immediate stock market gains.
NRx Pharmaceuticals (NRXP) shares surged over 26% in after-hours trading after announcing a forthcoming discussion about a regulatory milestone for its Preservative-Free Ketamine program. The company is set to hold a conference call and issue a press release before market open to detail the development and commercial launch plans for NRX-100, which is being developed for anesthesia and psychiatric treatments. Analysts maintain a positive outlook, with Ascendiant Capital reaffirming a Buy rating and raising the price target to $50.
NRx Pharmaceuticals Inc. has successfully completed commercial-scale manufacturing validation for its preservative-free injectable ketamine, an essential step toward supplying U.S. hospitals and clinics. The company has also completed an analysis showing two years of real-time stability, suggesting a potential shelf life of three years or longer. This milestone positions NRx to meet market demand if the FDA approves its generic drug application by the November 10, 2026, target date.
NRx Pharmaceuticals is awaiting a federal regulatory decision on November 10 for its preservative-free ketamine product, following minor labeling changes requested by the FDA. This development could help the company establish a domestic supply source for the medication, addressing current shortages and reliance on overseas production. NRx is also finalizing manufacturing validation runs in preparation for a potential commercial launch.